Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis

QR Code

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis

Objective: to analyze the efficacy of tofacitinib (TOFA) in patients with an advanced stage of rheumatoid arthritis (RA) and previous methotrexate (MTX) failure according to comprehensive clinical and laboratory examination.Patients and methods. Nineteen patients (11 women and 8 men aged 29 to 71 ye...

Full description

Saved in:

Bibliographic Details
Main Authors:	I. V. Menshikova, V. V. Strogonova
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2019-05-01
Series:	Современная ревматология
Subjects:	rheumatoid arthritis inefficiency of treatment janus kinase inhibitors tofacitinib
Online Access:	https://mrj.ima-press.net/mrj/article/view/914
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

Ultrasound Evaluation of Therapeutic Response to Tofacitinib and Upadacitinib in Patients with Rheumatoid Arthritis—Real-Life Clinical Data
by: Vladimira Boyadzhieva, et al.
Published: (2025-05-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

Modern Management Approaches for Alopecia Areata
by: Eduard T. Ambarchyan, et al.
Published: (2024-12-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
by: A. E. Karateev, et al.
Published: (2021-09-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
by: A. E. Karateev, et al.
Published: (2020-05-01)

The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
by: Yu. A. Lushpaeva
Published: (2025-04-01)

Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
by: O. V. Shatalova, et al.
Published: (2017-04-01)

Synthesis and in vitro evaluation of novel pH-triggered biocompatible folate-chondroitin sulfate-dexamethasone copolymers for delivery of tofacitinib in rheumatoid arthritis
by: Zahra Ansarypour, et al.
Published: (2025-05-01)

ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)
by: A. S. Avdeeva, et al.
Published: (2020-06-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Baricitinib: key results of long-term use in rheumatoid arthritis
by: N. V. Chichasova, et al.
Published: (2024-08-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
by: G. A. Markova, et al.
Published: (2022-10-01)

Management of Generalized Vitiligo in Adolescent with Tofacitinib: Clinical Case
by: Eduard T. Ambarchyan, et al.
Published: (2024-11-01)

Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
by: A. S. Kolbin, et al.
Published: (2016-12-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01)

Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice
by: L. D. Vorobyeva, et al.
Published: (2022-07-01)

Polyarteritis nodosa is an unforeseen borderline paradoxical adverse reaction in a female patient with rheumatoid arthritis treated with tofacitinib
by: Yu. V. Muraviev, et al.
Published: (2019-09-01)

A case of psoriasis and atopic dermatitis-like rash induced by interleukin-17 and interleukin-23 inhibitors successfully controlled with upadacitinib
by: Toshiki Okazaki, MD, et al.
Published: (2025-09-01)

Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
by: Li B, et al.
Published: (2025-05-01)

EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)
by: E. L. Nasonov, et al.
Published: (2020-04-01)

New possibilities of thetherapy of patients with atopic dermatitis with Janus kinaseinhibitors
by: N. V. Zilberberg, et al.
Published: (2021-10-01)

THE ROLE OF VITAMINS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Zh. V. Maximova, et al.
Published: (2017-05-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

The association between genetic characteristics and treatment failure when switching from biologic disease-modifying antirheumatic drugs/Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2025-02-01)